- ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
- ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
- ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
- ACELYRIN, INC. Announces Leadership Transition
- ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
- ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
- ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
- ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
- ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
- ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
More ▼
Key statistics
On Wednesday, ACELYRIN Inc (SLRN:NSQ) closed at 4.15, 13.08% above the 52 week low of 3.67 set on Jun 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.12 |
---|---|
High | 4.20 |
Low | 4.02 |
Bid | 4.02 |
Offer | 4.14 |
Previous close | 4.12 |
Average volume | 999.54k |
---|---|
Shares outstanding | 99.03m |
Free float | 84.23m |
P/E (TTM) | -- |
Market cap | 407.99m USD |
EPS (TTM) | -2.59 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼